Rapamycin treatment linked to changes in energy and inflammation processes and reduced fatigue in ME/CFS patients: early phase-II study results

Low-dose rapamycin significantly reduced fatigue-related clinical symptoms in ME/CFS subjects during a phase II observational pilot trial.

• Fatigue-related symptoms were notably decreased in subjects taking low-dose rapamycin.
• The exact molecular mechanism behind these effects is still unclear.
• Increased levels of purines may be associated with heightened oxidative stress in ME/CFS patients.
• It remains uncertain whether rapamycin influences purine production and alleviates disease symptoms.

Simplified